Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb-Mar;21(1):15-9.

The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease

Affiliations
Review

The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease

John W Ward. Top Antivir Med. 2013 Feb-Mar.

Abstract

Society faces an immense burden of hepatitis C virus (HCV) infection-related morbidity and mortality. Transmission of HCV is ongoing, and the incidence of HCV infection has been increasing in recent years. New therapies for treating HCV infection hold considerable promise for increasing cure rates and thus reducing HCV transmission. However, many persons with HCV infection in the United States are unaware of their infection status. The Centers for Disease Control and Prevention (CDC) recently expanded its HCV testing recommendations to include 1-time HCV testing for individuals born between 1945 and 1965, a population with a 3% prevalence of infection. Linkage to care and treatment for those identified with infection through testing would have a profound impact in reducing HCV disease burden. Coordinated efforts by public health agencies, clinical care providers, laboratories, and payers are necessary to improve primary and secondary prevention of HCV disease. This article summarizes a presentation by John W. Ward, MD, at the IAS-USA live continuing medical education program held in Atlanta, Georgia, in October 2012.

PubMed Disclaimer

Conflict of interest statement

Financial Affiliations: Dr Ward has no relevant financial affiliations to disclose. (Updated 3/20/13)

Figures

Figure 1.
Figure 1.
Future burden of hepatitis C virus (HCV)-related morbidity and mortality in the United States. DCC indicates decompensated cirrhosis; HCC, hepatocellular carcinoma. Adapted from Rein DB et al.
Figure 2.
Figure 2.
Age distribution of confirmed hepatitis C virus (HCV) cases in Massachusetts in 2002 (top) and 2009 (bottom). Adapted from Centers for Disease Control and Prevention.
Figure 3.
Figure 3.
Estimated 10-year relative reduction in hepatitis C virus (HCV) prevalence among injection drug users (IDUs) according to number of HCV-infected IDUs treated annually with assumed sustained virologic response rate of 62.5%. Adapted from Martin et al.
Figure 4.
Figure 4.
Comparison of cost-effectiveness of hepatitis C virus (HCV) strategy compared with other routine preventive services. QALY indicates quality-adjusted life-year. Adapted from http://www.prevent.org/National-Commission-on-Prevention-Priorities/Rankings-of-Preventive-Services-for-the-US-Population.aspx. Accessed December 4, 2012.

References

    1. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43(1):66-72. - PubMed
    1. Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep. 2011;60(17):537-541. - PubMed
    1. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137-1144. - PubMed
    1. Perz JF, Grytdal S, Beck S, et al. Case-control study of hepatitis B and hepatitis C in older adults: Do healthcare exposures contribute to burden of new infections? Hepatology. 2013;57(3):917-924. - PubMed
    1. Scheinmann R, Hagan H, Lelutiu-Wein-berger C, et al. Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend. 2007;89(1):1-12. - PMC - PubMed

LinkOut - more resources